SCHEMBL3136226

SCHEMBL3136226

O=C(O)Cn1cnc2c(=O)[nH]c(NC(=O)OC(c3ccccc3)c3ccccc3)nc21

nearest known ligand 0.64

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TK1 P04183 1/20 0.46
MEN1 O00255 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3139870 0.83 MEN1 (0.48) TK1MEN1TSHRKMT2A
SCHEMBL24540183 0.79 MEN1 (0.50) TK1MEN1TSHRKMT2A
SCHEMBL3820444 0.79 STAT3 (0.38)
SCHEMBL3457921 0.78 MEN1 (0.50) TK1MEN1TSHRKMT2A
SCHEMBL3133440 0.77 TDP1 (0.43) KMT2A
SCHEMBL30089845 0.77 TDP1 (0.43) KMT2A
SCHEMBL4843329 0.76 TK1 (0.32) TK1MEN1TSHRKMT2A
SCHEMBL3134619 0.76 MEN1 (0.52) TK1MEN1TSHRKMT2A
SCHEMBL21525080 0.76 TK1 (0.33) TK1MEN1TSHRKMT2A
SCHEMBL28478877 0.76 SLC2A1 (0.36) MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114685606-A Synthetic method of peptide nucleic acid guanine monomer 苏州怡彼得生物技术有限公司 2022-07-01 CN claimed
CN-114685606-A Synthetic method of peptide nucleic acid guanine monomer 苏州怡彼得生物技术有限公司 2022-07-01 CN disclosed
CN-114685606-A Synthetic method of peptide nucleic acid guanine monomer 苏州怡彼得生物技术有限公司 2022-07-01 CN disclosed
EP-2174936-B1 PNA monomer and precursor PANAGENE INC (KR) 2013-09-04 EP disclosed
EP-2174936-A1 PNA monomer and precursor Panagene, Inc. (KR) 2010-04-14 EP disclosed
EP-1501812-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-12-30 EP disclosed
EP-1651642-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-11-04 EP disclosed
US-7411065-B2 Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids PANAGENE, INC. (KR) 2008-08-12 US disclosed
US-7371860-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2008-05-13 US disclosed
US-7371859-B2 Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields PANAGENE, INC. (KR) 2008-05-13 US disclosed
US-20050283005-A1 PNA monomer and precursor KIM SUNG K 2005-12-22 US disclosed
US-6969766-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-29 US disclosed
US-20050250785-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-10 US disclosed
US-20050250786-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-11-10 US disclosed
US-20050026930-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-02-03 US disclosed
WO-2005009998-A1 PNA MONOMER AND PRECURSOR PANAGENE INC. (US) 2005-02-03 WO disclosed
EP-1501812-A1 PNA MONOMER AND PRECURSOR Panagene, Inc. (KR) 2005-02-02 EP disclosed
US-20030225252-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2003-12-04 US disclosed
WO-2003091231-A1 PNA MONOMER AND PRECURSOR PANAGENE, INC. (US) 2003-11-06 WO disclosed
US-20030195332-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195332-A1 PNA monomer and precursor RNGTT, NGLY1, NCL TK1 454/4885MEN1 961/4885TSHR 954/4885
US-20050283005-A1 PNA monomer and precursor PNISR, RNGTT, POLL TK1 211/4885MEN1 3369/4885TSHR 488/4885
US-20050250785-A1 PNA monomer and precursor PNISR, RNGTT, POLL TK1 211/4885MEN1 3369/4885TSHR 488/4885
US-20030225252-A1 PNA monomer and precursor PNISR, RNGTT, NCL TK1 242/4885MEN1 3281/4885TSHR 372/4885
US-20050026930-A1 PNA monomer and precursor RNGTT, POLL, NSUN3 TK1 584/4885MEN1 1967/4885TSHR 379/4885
US-20050250786-A1 PNA monomer and precursor PNISR, RNGTT, NPR1 TK1 171/4885MEN1 3505/4885TSHR 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.